Clinical trials: Myelodysplasia
Acute Leukemia, Chronic Leukemia
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed…
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT03588936
- Testing
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical College of Wisconsin
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.
- Trial name
- NCT06932744
- Testing
- MY008211A tablets, Eculizumab Injection
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Leukemia
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
The goal of this clinical research study is to learn if pacritinib, either alone or in combination with azacitidine or decitabine, can help to control MDS. The safety of this drug and drug combination will also be studied.
- Trial name
- NCT02469415
- Testing
- Pacritinib, 5-azacitidine, Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Recent studies of conventional chemotherapy for infants with high-risk hematologic malignancies show that the long-term disease-free survival is low.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00145626
- Testing
- Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Acute Myeloid Leukemia
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
- Conditions
- Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05061147
- Testing
- MAX-40279-01
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Maxinovel Pty., Ltd.
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Myelodysplastic Syndromes
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.
- Trial name
- NCT02228525
- Testing
- selinexor (KPT-330)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Myelodysplastic Syndromes
Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
There are currently no licensed drugs in the EU to treat thrombocytopenia in MDS patients classified as IPSS low/int-1. Prior studies with romiplostim (a TPO receptor agonist) in MDS found that baseline concentration of TPO as…
- Trial name
- EUROPE (NCT02335268)
- Testing
- N-Plate / romiplostim
- Where
- 36 sites in France, Germany
- Volunteers
- 77 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Leukemia, Myeloid, Acute, Refractory AML
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with…
- Conditions
- Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2
- Trial name
- TUSCANY (NCT03850574)
- Testing
- Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 240 people
- Sponsor
- Aptose Biosciences Inc.
Myelodysplastic Syndromes
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome
The purpose of this study is to investigate the overall response rate (ORR) and safety when treating patients with myelodysplastic syndrome with decitabine.
- Trial name
- NCT01400633
- Testing
- decitabine injection
- Where
- 16 sites in South Korea
- Volunteers
- 156 people
- Sponsor
- Janssen Korea, Ltd., Korea
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
AML, ALL
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood…
- Conditions
- AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01012492
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Boston Children's Hospital
Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS
To assess the safety and efficacy of FLU-BU-MEL as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with untreated MDS-EB or IPSS-R that is intermediate-risk (>3.5 points), high-risk, or…
- Conditions
- Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes
- Trial name
- NCT06247917
- Testing
- Fludarabine, Busulfan and Melphalan
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Acute Leukemia, Chronic Leukemia
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well…
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas
- Trial name
- NCT02169791
- Testing
- MLN9708
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.
Hematologic Malignancy, Myelodysplastic Syndromes
Removing Transfusion Dependence as a Barrier to Hospice Enrollment
Hospice care at the end of life (EOL) includes a multidisciplinary team that helps patients and families focus on symptom control and quality of life. For patients with "solid" (e.g.
- Conditions
- Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Lymphoma
- Trial name
- BRUOG-407 (NCT05063591)
- Testing
- Transfusion support
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Adam Olszewski
MDS
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Treatment of patients with WHO defined IPSS int 2 and high risk MDS , AML with 20-30% marrow blasts and CMML type 2, after failure of azacitidine or decitabine exposure for at least 6 courses, or relapse after initial response.
- Trial name
- NCT02197676
- Testing
- SGI-110 administration
- Where
- 27 sites in France
- Volunteers
- 56 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
This phase II trial studies how well topotecan hydrochloride and carboplatin with or without veliparib work in treating patients with myeloproliferative disorders that have spread to other places in the body and usually cannot be…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03289910
- Testing
- Carboplatin, Topotecan, Topotecan Hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.